Your browser doesn't support javascript.
loading
Renal Ewing sarcoma treated with apatinib.
Zhao, Yang; Chen, Ye; Cheng, Ke; Li, Zhi-Ping; Zeng, Hao; Liu, Ji-Yan.
Afiliação
  • Zhao Y; The State Key Laboratory of Biotherapy, Department of Medical Oncology, West China Medical School, Cancer Center.
  • Chen Y; The State Key Laboratory of Biotherapy, Department of Medical Oncology, West China Medical School, Cancer Center.
  • Cheng K; The State Key Laboratory of Biotherapy, Department of Medical Oncology, West China Medical School, Cancer Center.
  • Li ZP; The State Key Laboratory of Biotherapy, Department of Medical Oncology, West China Medical School, Cancer Center.
  • Zeng H; Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Liu JY; The State Key Laboratory of Biotherapy, Department of Medical Oncology, West China Medical School, Cancer Center.
Anticancer Drugs ; 29(7): 702-704, 2018 08.
Article em En | MEDLINE | ID: mdl-29782348
Renal Ewing sarcoma (RES) is an extremely rare disease. The standard treatment for this disease is lacking, and clinical experience needs to be accumulated. Here, we report a case of RES that rapidly developed to metastatic disease and was refractory to radiotherapy and chemotherapy; however, the case obtained a partial response based on Choi criteria by orally taking antiangiogenic drug apatinib. Our case suggests that apatinib may be a therapeutic option for RES.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Sarcoma de Ewing / Neoplasias Renais / Antineoplásicos Limite: Adult / Humans / Male Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridinas / Sarcoma de Ewing / Neoplasias Renais / Antineoplásicos Limite: Adult / Humans / Male Idioma: En Revista: Anticancer Drugs Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2018 Tipo de documento: Article